Payment overview · 2025
General Payments
$943.40
39 reported records · 4 companies
Healthcare provider profile · identity verified
Gerald R Hamwi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1467447714
Verified facts
What the public records show
CMS Open Payments records show Gerald R Hamwi, MD received $943.40 in general payments during 2025 across 39 reported records.
ViiV Healthcare Company accounted for 64.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Shingrix.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 951 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $604.07 | 64.0% | 24 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $298.12 | 31.6% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.13 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.08 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $943.40 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $372.51 | 13 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $136.20 | 5 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $95.36 | 6 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $43.90 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 951 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
951 | 92 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
101 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 951 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 541 | 53 |
| Gabapentin | Gabapentin | 322 | 34 |
| Finasteride | Finasteride | 279 | 27 |
| Omeprazole | Omeprazole | 273 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 28 |
| Lisinopril | Lisinopril | 247 | 22 |
| Fluconazole | Fluconazole | 245 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 27 |
| Ibuprofen | Ibuprofen | 222 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 22 |
| Acyclovir | Acyclovir | 203 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 199 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 30 |
| Trazodone Hcl | Trazodone Hcl | 183 | 18 |
| Tadalafil | Tadalafil | 177 | 16 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 170 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 16 |
| Lorazepam | Lorazepam | 162 | 20 |
| Tivicay | Dolutegravir Sodium | 157 | 14 |
| Pregabalin | Pregabalin | 153 | 11 |
| Losartan Potassium | Losartan Potassium | 152 | 15 |
| Ozempic | Semaglutide | 151 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 26 |
| Pifeltro | Doravirine | 143 | 14 |
| Juluca | Dolutegravir/Rilpivirine | 138 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 134 | 19 |
| Benazepril Hcl | Benazepril Hcl | 129 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 117 | 13 |
| Metformin Hcl Er | Metformin Hcl | 117 | 12 |
| Valacyclovir | Valacyclovir Hcl | 105 | 14 |
| Descovy | Emtricitabine/Tenofov Alafenam | 101 | 11 |
| Metformin Hcl | Metformin Hcl | 101 | suppressed |
| Bupropion Xl | Bupropion Hcl | 99 | suppressed |
| Lamotrigine | Lamotrigine | 98 | suppressed |
| Jardiance | Empagliflozin | 88 | suppressed |
| Alprazolam | Alprazolam | 87 | suppressed |
| Mirtazapine | Mirtazapine | 83 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 78 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 78 | 11 |
| Farxiga | Dapagliflozin Propanediol | 76 | suppressed |
| Clonazepam | Clonazepam | 74 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 74 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 69 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 69 | suppressed |
| Testosterone | Testosterone | 69 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | suppressed |
| Temazepam | Temazepam | 59 | suppressed |
| Furosemide | Furosemide | 58 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 58 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 54 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Famotidine | Famotidine | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 48 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 41 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Loperamide | Loperamide Hcl | 40 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 16 |
| Valsartan | Valsartan | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 27 | suppressed |
| Nevirapine Er | Nevirapine | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Mytesi | Crofelemer | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Dapsone | Dapsone | 25 | suppressed |
| Imiquimod | Imiquimod | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Sumatriptan | Sumatriptan | 20 | suppressed |
| Estradiol Valerate | Estradiol Valerate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Meloxicam | Meloxicam | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Armodafinil | Armodafinil | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Isentress | Raltegravir Potassium | 13 | suppressed |
| Isentress Hd | Raltegravir Potassium | 13 | suppressed |
| Lamivudine | Lamivudine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Ritonavir | Ritonavir | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $943.40 · 39 records | ViiV Healthcare Company | APRETUDE, AREXVY, Biktarvy, CABENUVA, DOVATO, SHINGRIX, Saxenda, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error